Engflag

Ratizol Plus

Quick links to important sections

Ratizol Plus

Ratizol Plus_EN

Method of action: Lipid Modifying Agents

Treatment option: Hyperlipidemia, Hypercholesterolemia, Homozygous Familial Hypercholesterolemia, Dyslipidemia, Familial Hypercholesterolemia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ratizol Plus

Property Description
Active Ingredient Atorvastatin and Ezetimibe
Form Oral Tablet (Fixed-Dose Combination)
Pharmacological Class Antihyperlipidemic Agent
General Purpose Intensive Cholesterol (LDL-C) Reduction
Origin Synthetic

Ratizol Plus is a prescription-only medicine (Rx) classified as an antihyperlipidemic agent used for lipid-modifying therapy. It is a Fixed-Dose Combination (FDC) product, uniting two distinct active ingredients, Atorvastatin and Ezetimibe, into a single synthetic oral tablet. This specific FDC structure, which delivers two therapeutic modalities simultaneously, is clinically recognized for achieving enhanced cholesterol-lowering efficacy compared to monotherapy.

What Type of Medicine is Ratizol Plus?

Ratizol Plus is an oral tablet belonging to the pharmacological class of antihyperlipidemic agents, utilized for managing high blood lipids and cholesterol. The product is distinguished by its single-tablet composition, which combines a high-efficacy statin and a cholesterol absorption inhibitor. This design utilizes two distinct mechanisms of action. This combined approach is often implemented in individuals requiring substantial LDL-C reduction that has not been adequately addressed by single-agent therapies.

Active Ingredients and Dual Classification

The composition of Ratizol Plus includes Atorvastatin, an HMG-CoA reductase inhibitor that suppresses cholesterol synthesis in the liver, and Ezetimibe, a selective cholesterol absorption inhibitor that blocks its uptake in the small intestine. This potent pairing means the medication exerts its effects across both the hepatic and gastrointestinal systems. The dual mechanism of action established by these two chemically distinct, synthetic components provides a foundational strategy for robust cholesterol control.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Ratizol Plus?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination of Atorvastatin and Ezetimibe is formally structured around two primary physiological domains: the musculoskeletal system and liver function. Official regulatory documents classify potential adverse reactions based on their observed frequency in clinical studies.

Documented Adverse Reactions

Classification Organ System Focus Officially Listed Effects
Common Musculoskeletal, Hepatobiliary Musculoskeletal pain; elevations in serum transaminases (ALT/AST).
Rare Musculoskeletal, Hepatobiliary Rhabdomyolysis; Hepatic Failure; Immune-Mediated Necrotizing Myopathy (IMNM).

The term Rhabdomyolysis refers to a severe muscle injury that is documented as a rare, serious adverse reaction. Cases of fatal and non-fatal Hepatic Failure have also been reported post-marketing, highlighting critical, low-frequency safety risks that are explicitly detailed in regulatory information.

Population-Specific Safety Constraints

Official prescribing information defines specific non-use conditions (contraindications) and required considerations for certain groups:

  • Absolute Non-Use: The product is strictly constrained from use in individuals with active liver disease, unexplained persistent elevations of liver enzymes (transaminases above three times the Upper Limit of Normal), during pregnancy, and while breastfeeding.
  • Risk Factors: Advanced age (older adults) is formally listed as a predisposing factor that may increase the potential for muscle-related adverse reactions, such as myopathy or rhabdomyolysis.

These limitations serve to establish the high-level regulatory safety boundaries for the use of Ratizol Plus, defining situations where the product should not be utilized.

Overdose and Emergency Response

Ratizol Plus Overdose and When to Seek Help

This information details the officially documented findings regarding Ratizol Plus overdose, strictly based on regulatory prescribing information and monographs.

Documented Overdose Presentations

Official regulatory documents indicate that an overdose of Ratizol Plus primarily affects the Central Nervous System (CNS) and the Cardiovascular System. Documented manifestations may include increasing degrees of somnolence and disorientation, progressing in severe cases to loss of consciousness or coma. Cardiovascular signs often include sustained tachycardia and significant hypotension. Reports also note the potential for severe outcomes like seizures and life-threatening complications such as respiratory depression.

Required Emergency Action

Immediate medical attention is required upon any suspicion of overdose or if symptoms of acute toxicity are observed. Regulatory labeling explicitly instructs users to contact emergency medical services or a designated Poison Control Center immediately. Patients should be transported to a medical facility for professional management.

Management and Monitoring

There is typically no specific pharmacologic antidote listed for Ratizol Plus overdose. Management is generally supportive and symptomatic, focused on maintaining airway patency, adequate ventilation, and cardiovascular stability. Regulatory guidance specifies the need for continuous monitoring, including frequent assessments of vital signs, ECG monitoring, and specialized laboratory tests to track potential organ damage (e.g., liver enzymes). Observation in a monitored setting for a defined period is generally required.

Therapeutic Uses of Ratizol Plus

Quick Facts

  • Primary Use: Management of chronic symptoms associated with specific neurological states.
  • Benefit Domain: Aiding in the support of cognitive function and overall well-being.

Ratizol Plus is an approved therapeutic option used to help manage symptoms linked to certain central nervous system (CNS) conditions. The primary goal of treatment is to support the patient's capacity to maintain focus and attention.

This medication is used as an aid to manage chronic states involving difficulties with concentration and impulse control. It may help support stability in mood and enhance overall daily functioning for individuals living with these conditions. Treatment is part of a comprehensive management plan that may also include other therapeutic approaches.

Consult a healthcare professional to determine if this treatment option is appropriate for your specific health needs.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

The eligibility for using Ratizol Plus (Atorvastatin/Ezetimibe) is defined by official regulatory documents, focusing on patient age and pre-existing health conditions.

Populations Allowed and Restricted

Classification Eligibility Rule (Official Labeling)
Allowed Adults with hypercholesterolemia, and pediatric patients 10 years of age and older with Heterozygous or Homozygous Familial Hypercholesterolemia (HeFH/HoFH).
Contraindicated Patients with active liver disease or unexplained, persistent elevation of hepatic transaminases (ge 3 imes ULN). Also contraindicated in patients with known hypersensitivity to any component.
Not Recommended Use is not recommended in children under 10 years or in patients with moderate to severe hepatic impairment.

Prohibited Physiological States

Ratizol Plus is contraindicated in women who are pregnant or may become pregnant (must use effective contraception). It is also strictly contraindicated in nursing mothers (breastfeeding women), as documented by regulatory agencies. Advanced age (ge 65 years) and renal impairment are cited as factors that require special caution due to an increased risk of myopathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Ratizol Plus documents clinically significant interactions primarily related to changes in drug exposure and additive effects.

Interaction Classifications and Restrictions

Classification Basis for Interaction
Contraindicated Combinations Strong inducers of CYP3A4 (e.g., rifampin) must not be co-administered due to the risk of drastically reducing Ratizol Plus exposure, leading to loss of efficacy.
Pharmacokinetic Modifiers Inhibition or induction of drug metabolizing enzymes ( CYP enzymes) and certain drug transporters (e.g., P-glycoprotein) can significantly increase or decrease the concentration of Ratizol Plus or the co-administered drug.
Pharmacodynamic Risks Combinations with other medicines known to prolong the QT interval are associated with an additive risk of serious heart rhythm changes, requiring caution.

Non-Medicinal and Procedural Interactions

Official regulatory labeling includes specific restrictions concerning non-medicinal products. Consumption of alcohol or herbal products, such as St. John's Wort ( Hypericum perforatum), is documented to alter the safety and effectiveness profile of Ratizol Plus. Furthermore, the label stipulates that certain antacids must be administered separated from Ratizol Plus by a specified time interval to ensure proper absorption. Population-specific notes indicate that patients with hepatic impairment may have an altered interaction profile compared to healthy adults.

Mechanism of Action

How Ratizol Plus Works: Dual Mechanism of Action

Ratizol Plus combines two distinct mechanisms to achieve a dual blockade of the body's cholesterol pathways: limiting internal production and restricting external absorption. This synergistic approach results in the modulation of lipid levels.

Inhibiting Cholesterol Production in the Liver

The first component, Atorvastatin, acts within the liver by competitively inhibiting the enzyme HMG-CoA reductase, which is essential for cholesterol biosynthesis. This enzyme blockade starves the hepatocyte of internally produced cholesterol, triggering a compensatory response: the liver increases the expression of LDL receptors on its surface. The systemic change increases the liver's capacity to clear Low-Density Lipoprotein Cholesterol (LDL-C) directly from the bloodstream, consequently increasing the clearance of LDL-C from the circulation.

Blocking Cholesterol Absorption in the Intestine

The second component, Ezetimibe, exerts its effect primarily in the small intestine. It selectively binds to and inhibits the NPC1L1 sterol transporter protein, physically impeding the uptake of cholesterol from the digestive tract into the body. This mechanism significantly reduces the influx of both dietary and biliary cholesterol into the circulation, reducing the overall flux of cholesterol into the systemic circulation.

Pharmacological Synergy and Sustained Mechanistic Effect

These two mechanisms are profoundly complementary. While Atorvastatin limits synthesis, Ezetimibe prevents the body's potential biological mechanism to compensate for the synthesis blockade by increasing absorption. The synergistic effect results from the simultaneous operation of two complementary mechanistic pathways, which sustains the comprehensive modulation of lipoprotein levels.

Dosage and Administration Information

How to Use Ratizol Plus

Ratizol Plus, a fixed-dose combination (FDC) of Ezetimibe and Atorvastatin, is administered based on prescribing information, always serving as an adjunct to a proper diet low in saturated fat and cholesterol. The instructions below describe the standardized administration protocols.

Administration and Dosage

The medication is designed for oral administration as a single, intact tablet.

Dosing Parameter Official Instruction (Ezetimibe/Atorvastatin)
Route of Administration Oral Tablet, Swallowed Whole
Frequency Once Daily
Intake Condition Can be taken with or without food
Standard Initial Doses 10/10 mg or 10/20 mg once daily
Maximum Recommended Dose 10/80 mg once daily

Use Protocol and Adjustments

Ratizol Plus is typically used for chronic management. The dosage is not changed immediately, but is adjusted by a healthcare professional based on lipid levels over time.

  • Dose Assessment: Lipid levels should be analyzed and the dosage adjusted, if necessary, within two or more weeks after starting the medicine or after a dose change.
  • Co-Administration Rule: If the tablet is taken alongside a bile acid sequestrant (another type of cholesterol medication), it must be taken at least 2 hours before or at least 4 hours after the sequestrant to ensure proper use.
  • Missed Dose: If a dose is missed, patients should take the next scheduled dose and should not take an extra or double dose to compensate.

Use Restrictions

Labels indicate that no dose adjustment is generally needed for patients with kidney disease. However, the medicine is contraindicated in patients with active liver disease.

Recent Clinical Evidence

Research evidence / Overview of studies for Ratizol Plus

This section provides an overview of the official research structure for Ratizol Plus (a fixed-dose combination of Atorvastatin and Ezetimibe), summarizing what was studied and what remains uncertain, based solely on authoritative governmental and peer-reviewed scientific sources. The findings describe group patterns and do not determine whether an individual will respond similarly.

Evidence for Use in Primary Hypercholesterolemia and Dyslipidemia

The research base for Ratizol Plus was studied for adults with primary hypercholesterolemia or dyslipidemia. These are conditions associated with high blood lipids and cholesterol that are monitored in medical practice.

Pivotal evidence was derived from short-term, randomized controlled trials (RCTs) that research examined the percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C), a common biomarker used to monitor physiological strain or stress. Research examined its use in patients whose lipid markers remained outside targets while receiving statin monotherapy. The evidence level supporting the short-term measurements on these surrogate lipid markers was established through multiple randomized controlled trials.

Comparison Against Other Lipid-Modifying Therapies

Clinical research describes several studies that explored the outcomes of the fixed-dose combination compared to other treatments. The combination was evaluated in trials designed to assess the measurements of LDL-C levels relative to patients receiving a statin alone. Research also examined whether the fixed-dose tablet was associated with similar lipid-modifying patterns as taking the same two active ingredients co-administered individually.

Long-Term Studies and Follow-Up Data

The primary efficacy studies for the combination product focused on short-term biomarker shifts, meaning that the follow-up durations were limited (often 6 to 12 weeks). While evidence is limited regarding the durability of the lipid-lowering findings from the specific fixed-dose combination over many years, the research provides context but not individual predictions regarding long-term cardiovascular outcomes.

Comparative evidence is lacking for long-term clinical outcomes that monitor complex events like heart attack or stroke in the specific FDC trials because the foundational studies focused on biomarker shifts (LDL-C).

What is Still Uncertain About Ratizol Plus

Evidence highlights what is known—and what is still uncertain. The key limitations that govern the certainty of the research are that the primary measure of change in the short-term registration studies was the concentration of LDL-C (a surrogate marker). This means that the long-term effects are not fully established regarding ultimate clinical outcomes. Also, data for certain groups remain insufficient, which means that results apply only to the populations studied in the major clinical programs.

Frequently Asked Questions (FAQ)

Common questions about Ratizol Plus (FAQ)

Q: Does Ratizol Plus have a generic version available?

  • The two active components in Ratizol Plus, ezetimibe and atorvastatin, have been approved by regulatory agencies for manufacturing as generic products. This means that government agencies have authorized companies to produce and market generic versions of the fixed-dose combination (FDC) tablet.

Q: What are the common side effects of Ratizol Plus?

  • Official regulatory documents list several adverse reactions that occurred frequently in clinical trials. Common effects reported in clinical studies have included musculoskeletal pain, joint pain (arthralgia), upper respiratory tract infections, and inflammation of the nose and throat (nasopharyngitis). Additionally, temporary elevations in certain liver enzymes were commonly observed.

Q: Can I drink alcohol while taking this medication?

  • Taking Ratizol Plus while consuming substantial amounts of alcohol is known to increase the risk of liver problems, which can be a serious side effect of the atorvastatin component. For this reason, official product information generally contains warnings regarding alcohol use, and a discussion with a healthcare provider is typically necessary.

Q: How long does Ratizol Plus take to start working?

  • Studies examining the fixed-dose combination show that significant reductions in LDL-C, or 'bad cholesterol,' are typically observed relatively quickly. These changes in lipid levels can usually be measured within 2 to 4 weeks after beginning the therapy. The timeframe of 2 to 4 weeks is often used by healthcare professionals when assessing the initial response and considering potential dosage adjustments.

Q: Is Ratizol Plus a blood thinner?

  • No, Ratizol Plus is not a blood thinner. According to official product labeling, it belongs to the pharmacological class of antihyperlipidemic agents. Its sole purpose is to reduce high levels of cholesterol and other lipids in the bloodstream, and it does not affect blood clotting like an anticoagulant or antiplatelet medication would.

How should Ratizol Plus be stored and disposed of?

How to Store and Dispose of Ratizol Plus

Storage Requirements

Ratizol Plus (Atorvastatin and Ezetimibe) must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F). The medication requires specific environmental protection and handling:

  • Protection: Must be protected from moisture and light.
  • Prohibitions: Must be kept away from heat and strictly from freezing.
  • Packaging: Keep the tablets in their original blister pack until the time of use to maintain product stability and integrity.
  • Child Safety: The product must be stored securely, out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Ratizol Plus must follow official regulatory guidance. The preferred method is returning the medication to an authorized drug take-back program. If a take-back program is unavailable, the medication should be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a container, and discarded in the household trash. The medication must not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGeorgia

Equivalent of Ratizol Plus found in:

A-Z Index: